Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

International staging system for multiple myeloma.

Philip R Greipp1, Jesus San Miguel, Brian G M Durie

  • 1Mayo Clinic College of Medicine and Eastern Cooperative Oncology Group, Rochester, MN, USA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|April 6, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancer.

The British journal of dermatology·2026
Same author

Impact of SARS-CoV-2 vaccination on monoclonal gammopathy of undetermined significance: results from the population-based iStopMM study.

Blood cancer journal·2026
Same author

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Blood cancer journal·2026
Same author

Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study.

Leukemia·2025
Same author

Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702).

Blood·2025
Same author

Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS.

Blood advances·2025
This summary is machine-generated.

A new International Staging System (ISS) for multiple myeloma uses serum beta2-microglobulin and serum albumin to classify patients into three stages. This simple system aids in patient stratification and treatment planning for better outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Multiple myeloma requires a standardized international staging system for patient classification.
  • Existing systems may lack simplicity or broad applicability.

Purpose of the Study:

  • To develop and validate a simple, reliable, and internationally applicable staging system for multiple myeloma.
  • To improve patient classification and stratification for treatment and research.

Main Methods:

  • Gathered clinical and laboratory data from 10,750 previously untreated symptomatic myeloma patients across 17 global institutions.
  • Evaluated prognostic factors using univariate and multivariate analyses.
  • Explored three modeling approaches, including tree-based survival assessment, to create the staging system.

Related Experiment Videos

Main Results:

  • Serum beta2-microglobulin (Sbeta2M) and serum albumin emerged as key predictors of survival.
  • Developed a three-stage International Staging System (ISS) based on Sbeta2M and serum albumin levels.
  • Validated the ISS across diverse patient groups and geographical locations, showing superior performance compared to the Durie/Salmon system.

Conclusions:

  • The new ISS is simple, utilizing readily available variables (Sbeta2M and serum albumin).
  • The ISS provides a robust three-stage classification with distinct median survival rates (Stage I: 62 months, Stage II: 44 months, Stage III: 29 months).
  • The ISS is recommended for widespread adoption due to its simplicity, reliability, and validated international applicability.